HUMAN HERPES VIRUS 6 INFECTION IN ALLOGENEIC STEM CELL TRANSPLANTATION RECEIVING POST-TRASPLANT CYCLOPHOSPHAMIDE (EBMT 2026) - Mar 14, 2026 - Abstract #B107; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Clinical Trial Registry: Not Applicable. Epidemiology of HHV6 infection is changing in allo-HCT due to the new approaches in GvHD prophylaxis (PTCy regimen) and Letermovir prophylaxis for CMV infection (excellent control on CMV infection). Gastrointestinal infection is the most frequent organ presentation with a good response to antiviral treatment."
CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Transplantation
|
|
Maria Suárez-Lledó1,2,3; Ares Guardia4; Huxlhey Braulio Cabrera-García5; Virginia Rodíguez-Lorente1,2; Paola Charry1,2,3; Jhonny Manuel Carranza1; Adriana Cuartas1; Mónica Molina1; Laia Guardia1; Berta Sole1; Juan Manuel Torres1,2; Natalia Egri1,2; Francesc Fernández-Avilés1,2,3; Laura Rosiñol1,2,3; Carmen Martínez-Muñoz1,2,3; M Angeles Marcos1,2; Maria Queralt Salas1,2,3; Montserrat Rovira1,2,3
|